Business Context and Reporting Period
This Form 8-K Current Report was filed by GRI Bio, Inc. on February 19, 2025. The filing discloses a material corporate action involving a reverse stock split of the Company's common stock, which is traded on The Nasdaq Capital Market under the symbol "GRI."
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly a notice of a capital structure modification.
Material Changes
- Reverse Stock Split: The Company implemented a 1-for-17 reverse stock split of its common stock.
- Effective Date: The split became effective at 4:01 p.m. Eastern Time on February 21, 2025.
- Trading Resumption: Post-split trading began on The Nasdaq Capital Market on February 24, 2025.
- Adjustments: Proportionate adjustments were made to the exercise prices and share counts of outstanding stock options, warrants, and convertible securities.
- Fractional Shares: Stockholders entitled to fractional shares received cash payments based on the closing sales price on February 21, 2025.
- Identification: The new CUSIP number for the Common Stock is 3622AW 403.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure regarding the mechanics of the reverse stock split. The primary purpose of the filing is to notify security holders of the amendment to the Certificate of Incorporation.
Investor Verification Checklist
- Verify the new CUSIP number (3622AW 403) for trading and settlement purposes.
- Confirm the adjusted number of shares held and the adjusted exercise prices of any outstanding options or warrants.
- Check for cash payments received in lieu of fractional shares based on the February 21, 2025 closing price.
- Review the full text of the Certificate of Amendment (Exhibit 3.1) for complete legal terms.